Clinical Trial

Tirzepatide in PWS, HO and GNSO

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 16, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-27; most recent amendment 2025-09-12.
Trial Details
NCT Number NCT06901245
Lead Sponsor Grace Kim
Collaborators: Vanderbilt University Medical Center, Children's Hospitals and Clinics of Minnesota, Seattle Children's Hospital
Conditions Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
Enrollment 36 participants
Start Date 2025-05-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-16